Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: A prospective observational study

BMC Nephrology

Volumn 13, Issue 1, 2012, Pages

  De Nicola, Luca ^a   Conte, Giuseppe ^a   Russo, Domenico ^b   Gorini, Antonio ^c   Minutolo, Roberto ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c S Giovanni Evangelista Hospital   (Italy)

Author keywords

Angiotensin converting enzyme inhibitor; Angiotensin II receptor blocker; Chronic kidney disease; Paricalcitol; Proteinuria; Renin inhibitor

Indexed keywords

PARATHYROID HORMONE; PARICALCITOL;

ADD ON THERAPY; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL EVALUATION; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; LOW DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PARATHYROID HORMONE BLOOD LEVEL; PROSPECTIVE STUDY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SALT INTAKE; SODIUM EXCRETION; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

AGED; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; ERGOCALCIFEROLS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 84869183134     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-13-150     Document Type: Article

References (34)

1. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Levey AS, Cattran D, Friedman A, Miller WG, Sedor J, Tuttle K, Kasiske B, Hostetter T, Am J Kidney Dis 2009 54 205 226 10.1053/j.ajkd.2009.04. 029 19577347
2. Prognosis of CKD patients receiving outpatient nephrology care in Italy. De Nicola L, Chiodini P, Zoccali C, Borrelli S, Cianciaruso B, Di Iorio B, Santoro D, Giancaspro V, Abaterusso C, Gallo C, Conte G, Minutolo R, SIN-TABLE CKD Study Group, Clin J Am Soc Nephrol 2011 6 2421 2428 10.2215/CJN.01180211 21817127
3. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Ruggenenti P, Perna A, Remuzzi G, GISEN Group Investigators, Kidney Int 2003 63 2254 2261 10.1046/j.1523-1755.2003.00033.x 12753315 (Pubitemid 36605839)
4. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM, Circulation 2004 110 921 927 10.1161/01.CIR.0000139860.33974.28 15302780 (Pubitemid 39128617)
5. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D, J Am Soc Nephrol 2007 18 1540 1546 10.1681/ASN.2006050445 17409317 (Pubitemid 46717521)
6. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004 43 1 S230 15114537
7. Direct renin inhibition with aliskiren in hypertension and target organ damage. Müller DN, Luft FC, Clin J Am Soc Nephrol 2006 1 221 228 10.2215/CJN.01201005 17699210
8. The importance of the intrarenal renin-angiotensin system. Velez JC, Nat Clin Pract Nephrol 2009 5 89 100 10.1038/ncpneph1015 19065132
9. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic disease: pathophysiology and indications. Wolf G, Ritz E, Kidney Int 2005 67 799 812 10.1111/j.1523-1755. 2005.00145.x 15698420 (Pubitemid 41623305)
10. Metaanalysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Kunz R, Friedrich C, Wolbers M, Mann JF, Ann Intern Med 2008 148 30 48 17984482 (Pubitemid 351688350)
11. Antiproteinuric response to add-on aliskiren in proteinuric patients treated with dual blockade of the renin-angiotensin system: a 12-month prospective uncontrolled study. De Nicola L, Zamboli P, Bellizzi V, Stanzione G, Russo D, Nappi F, Minco M, Chiodini P, Conte G, Minutolo R, Am J Kidney Dis 2011 57 961 963 10.1053/j.ajkd.2011.02.384 21507536
12. Renoprotective effects of vitamin D analogs. Li YC, Kidney Int 2010 78 134 139 10.1038/ki.2009.175 19471320
13. Are vitamin D receptor agonists like angiotensin-converting enzyme inhibitors without side effects? Agarwal R, Kidney Int 2010 77 943 945 10.1038/ki.2010.77 20467430
14. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, Williams L, Batlle D, Kidney Int 2005 68 2823 2828 10.1111/j.1523-1755.2005.00755.x 16316359 (Pubitemid 43251029)
15. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, Light RP, Agarwal R, Hypertension 2008 52 211 212 10.1161/HYPERTENSIONAHA.108.115220 18606899
16. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N, Am J KidneyDis 2009 54 647 652 10.1053/j.ajkd.2009.04.036
17. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D, Lancet 2010 376 1543 1551 10.1016/S0140-6736(10)61032-X 21055801
18. Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis. Cheng J, Zhang W, Zhang X, Li X, Chen J, Clin J Am Soc Nephrol 2012 7 391 400 10.2215/CJN.03000311 22223607
19. Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. Bianchi S, Bigazzi R, Campese VM, Am J Kidney Dis 2010 55 671 681 10.1053/j.ajkd.2009.11.006 20097461
20. Role of remission clinics in the longitudinal treatment of CKD. Ruggenenti P, Perticucci E, Cravedi P, Gambara V, Costantini M, Sharma SK, Perna A, Remuzzi G, J Am Soc Nephrol 2008 19 1213 1224 10.1681/ASN.2007090970 18354029
21. European Society of Hypertension Working Group on Blood Pressure Monitoring: European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. OBrien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, Mengden T, Myers M, Padfield P, Palatini P, Parati G, Pickering T, Redon J, Staessen J, Stergiou G, Verdecchia P, J Hypertens 2003 21 821 848 10.1097/00004872-200305000-00001 12714851 (Pubitemid 36677141)
22. International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcomes (IDACO) Investigators: diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Kikuya M, Hansen TW, Thijs L, Björklund-Bodegård K, Kuznetsova T, Ohkubo T, Richart T, Torp-Pedersen C, Lind L, Ibsen H, Imai Y, Staessen JA, Circulation 2007 115 2145 2152 10.1161/CIRCULATIONAHA.106.662254 17420350 (Pubitemid 46659066)
23. Prevalence and clinical correlates of white coat hypertension in chronic kidney disease. Minutolo R, Borrelli S, Scigliano R, Bellizzi V, Chiodini P, Cianciaruso B, Nappi F, Zamboli P, Conte G, De Nicola L, Nephrol Dial Transplant 2007 22 2217 2223 10.1093/ndt/gfm164 17420167 (Pubitemid 47244699)
24. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC, Proc Natl Acad Sci USA 2008 105 15896 15901 10.1073/pnas.0803751105 18838678
25. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. Tan X, Wen X, Liu Y, J Am Soc Nephrol 2008 19 1741 1752 10.1681/ASN.2007060666 18525004
26. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Deb DK, Sun T, Wong KE, Ning G, Zhang Y, Kong J, Shi H, Chang A, Li YC, Kidney Int 2010 77 1000 1009 10.1038/ki.2010.22 20182412
27. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D, Kidney Int 2003 63 1483 1490 10.1046/j.1523-1755.2003.00878.x 12631365 (Pubitemid 36350014)
28. Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin-angiotensin- aldosterone system inhibition. Kim MJ, Frankel AH, Donaldson M, et al. Kidney Int 2011 80 851 860 10.1038/ki.2011.224 21832985
29. Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial. Liu LJ, Lv JC, Shi SF, Chen YQ, Zhang H, Wang HY, Am J Kidney Dis 2012 59 67 74 10.1053/j.ajkd.2011.09.014 22019331
30. Angiotensin II, and its receptors in the diabetic kidney. Burns KD, Am J Kidney Dis 2000 36 449 467 10977776
31. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. Huang XR, Chen WY, Truong LD, Lan HY, J Am Soc Nephrol 2003 14 1738 1747 10.1097/01.ASN.0000071512.93927.4E 12819233 (Pubitemid 36750469)
32. Achievement of target blood pressure levels in chronic kidney disease: a salty question? De Nicola L, Minutolo R, Bellizzi V, Zoccali C, Cianciaruso B, Andreucci VE, Fuiano G, Conte G, Am J Kidney Dis 2004 43 782 795 10.1053/j.ajkd.2004.01.009 15112168 (Pubitemid 38529615)
33. Salt intake and renal outcome in patients with progressive renal disease. Cianciaruso B, Bellizzi V, Minutolo R, Tavera A, Capuano A, Conte G, De Nicola L, Miner Electrolyte Metab 1998 24 296 301 10.1159/000057385 9554571 (Pubitemid 28108269)
34. Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia. Slatopolsky E, Cozzolino M, Lu Y, Finch J, Dusso A, Staniforth M, Wein Y, Webster J, Kidney Int 2003 63 2020 2027 10.1046/j.1523-1755.2003.00029.x 12753289 (Pubitemid 36605813)